BR112022024068A2 - Compostos de derivado de heteroarila e usos dos mesmos - Google Patents
Compostos de derivado de heteroarila e usos dos mesmosInfo
- Publication number
- BR112022024068A2 BR112022024068A2 BR112022024068A BR112022024068A BR112022024068A2 BR 112022024068 A2 BR112022024068 A2 BR 112022024068A2 BR 112022024068 A BR112022024068 A BR 112022024068A BR 112022024068 A BR112022024068 A BR 112022024068A BR 112022024068 A2 BR112022024068 A2 BR 112022024068A2
- Authority
- BR
- Brazil
- Prior art keywords
- heteroaryl derivative
- derivative compounds
- present disclosure
- her2
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210063733 | 2021-05-17 | ||
| PCT/KR2022/006994 WO2022245085A1 (ko) | 2021-05-17 | 2022-05-16 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024068A2 true BR112022024068A2 (pt) | 2023-12-05 |
Family
ID=84141801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024068A BR112022024068A2 (pt) | 2021-05-17 | 2022-05-16 | Compostos de derivado de heteroarila e usos dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12037330B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4342895A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7896880B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102607051B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667251A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022271388A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022024068A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180295A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298474A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014887A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI869674B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022245085A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN115667251A (zh) * | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL161662A0 (en) | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors) |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
| KR101247840B1 (ko) | 2008-02-22 | 2013-03-26 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타 조절제 |
| EP3205650B1 (en) | 2014-10-11 | 2021-08-04 | Shanghai Hansoh Biomedical Co., Ltd. | Egfr inhibitor, and preparation and application thereof |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| JP2020526499A (ja) | 2017-07-05 | 2020-08-31 | シーエス ファーマテック リミテッド | Egfrチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤 |
| US11440899B2 (en) | 2017-10-17 | 2022-09-13 | Merck Patent Gmbh | Pyrimidine TBK/IKKe inhibitor compounds and uses thereof |
| JP7109013B2 (ja) | 2019-03-19 | 2022-07-29 | ボロノイ インコーポレイテッド | ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物 |
| WO2020235902A1 (ko) * | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
| KR20210032093A (ko) | 2019-09-16 | 2021-03-24 | 제이투에이치바이오텍 (주) | Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 |
| US20230322753A1 (en) | 2020-09-18 | 2023-10-12 | Voronoi Inc. | Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient |
| KR20220085735A (ko) | 2020-12-14 | 2022-06-22 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| US20240262815A1 (en) | 2021-05-07 | 2024-08-08 | Voronoi Inc. | Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient |
| CN115667251A (zh) * | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
-
2022
- 2022-05-16 CN CN202280004578.7A patent/CN115667251A/zh active Pending
- 2022-05-16 CA CA3180295A patent/CA3180295A1/en active Pending
- 2022-05-16 BR BR112022024068A patent/BR112022024068A2/pt unknown
- 2022-05-16 JP JP2022573567A patent/JP7896880B2/ja active Active
- 2022-05-16 AU AU2022271388A patent/AU2022271388A1/en active Pending
- 2022-05-16 WO PCT/KR2022/006994 patent/WO2022245085A1/ko not_active Ceased
- 2022-05-16 EP EP22793620.0A patent/EP4342895A4/en active Pending
- 2022-05-16 KR KR1020220059638A patent/KR102607051B1/ko active Active
- 2022-05-16 MX MX2022014887A patent/MX2022014887A/es unknown
- 2022-05-16 IL IL298474A patent/IL298474A/en unknown
- 2022-05-16 US US17/927,324 patent/US12037330B2/en active Active
- 2022-05-17 TW TW111118417A patent/TWI869674B/zh active
-
2023
- 2023-11-22 KR KR1020230163623A patent/KR20230163335A/ko active Pending
-
2024
- 2024-01-16 US US18/414,371 patent/US12528799B2/en active Active
- 2024-06-01 US US18/731,285 patent/US12534457B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240317730A1 (en) | 2024-09-26 |
| US12534457B2 (en) | 2026-01-27 |
| TWI869674B (zh) | 2025-01-11 |
| TW202310845A (zh) | 2023-03-16 |
| US20240166640A1 (en) | 2024-05-23 |
| IL298474A (en) | 2023-01-01 |
| CN115667251A (zh) | 2023-01-31 |
| US20240025888A1 (en) | 2024-01-25 |
| AU2022271388A1 (en) | 2022-12-01 |
| US12037330B2 (en) | 2024-07-16 |
| KR20220156453A (ko) | 2022-11-25 |
| JP7896880B2 (ja) | 2026-07-29 |
| EP4342895A4 (en) | 2025-09-10 |
| CA3180295A1 (en) | 2022-11-24 |
| EP4342895A1 (en) | 2024-03-27 |
| KR20230163335A (ko) | 2023-11-30 |
| KR102607051B1 (ko) | 2023-11-30 |
| US12528799B2 (en) | 2026-01-20 |
| WO2022245085A1 (ko) | 2022-11-24 |
| JP2024519626A (ja) | 2024-05-21 |
| MX2022014887A (es) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| ECSP21055158A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria sobre cdk2 | |
| BR112023000770A2 (pt) | Inibidor de egfr | |
| BR112022011917A2 (pt) | Fluoroalquil-oxadiazois e seus usos | |
| BR112022023983A2 (pt) | Compostos terapêuticos | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| MX391655B (es) | Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo | |
| BR112017017888A2 (pt) | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| ECSP20010477A (es) | Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel | |
| MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| JOP20210269A1 (ar) | تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها | |
| BR112021019125A2 (pt) | Inibidores de prmt5 e usos dos mesmos | |
| MX384072B (es) | Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa. | |
| MX2019001579A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112017006690A8 (pt) | Composto derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BR112023001924A2 (pt) | Derivados de benzimidazol, método de preparo para os mesmos e uso médico dos mesmos | |
| BR112022025147A2 (pt) | Derivados de 4-etinilpiridina úteis como inibidores de gnc2 | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: PROMULGA-SE O ARQUIVAMENTO DA PETICAO DE ENTRADA NA FASE NACIONAL POR INTEMPESTIVIDADE DE APRESENTACAO DA PROCURACAO CONFORME DETERMINADO NO ART. 216 2O DA LEI 9.279/1996 E ART 13 DA PORTARIA INPI 39/2021. DESTA DATA, CORRE O PRAZO DE 60 (SESSENTA) DIAS PARA EVENTUAL RECURSO DO INTERESSADO CONFORME APRESENTADO NO ART. 212 DA LEI 9.279/1996 |
|
| B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.6.1 NA RPI NO 2715 DE 17/01/2023 POR TER SIDO INDEVIDA. |
|
| B25A | Requested transfer of rights approved |
Owner name: VORONOI INC. (KR) |